Congressman Sires Statement on the Passage of the Global Health Innovation Act of 2017
(Washington, D.C.) – H.R. 1660, the Global Health Innovation Act of 2017 passed the Senate by unanimous consent on December 20, 2018. Previously, H.R. 1660 passed the House of Representatives on January 18, 2018 by a vote of 423-2 and now awaits signature by the President to be enacted into law.
Rep. Albio Sires (D-NJ) and Rep. Mario Diaz-Balart (R-FL) introduced this legislation at the start of the 115th Congress to provide a bipartisan, modern update to the groundbreaking research and development in health care technology carried out by the United States Agency for International Development (USAID).
Rep. Sires stated: “As the 115th Congress comes to a close, I am proud that advancements towards an AIDS-free generation, an end to preventable maternal and childhood deaths, and the stop of lethal global epidemics are closer within our reach. Innovation in health care products by USAID increases the effectiveness of our foreign policy and progresses the health of millions around the world. Providing restructured oversight and transparency, the bipartisan legislation that I introduced with my friend Rep. Diaz-Balart now paves the way for American leadership at home and abroad.”
Rep. Diaz-Balart stated: “The Global Health Innovation Act provides USAID with better tools and resources when it comes to health care research and development. Innovative technology and medical devices are vital to America's leadership in global health, as well as our national security. I commend Congressman Sires for his willingness to work across the aisle and ongoing commitment to this issue that is central to making the United States a stronger partner to our allies.”